Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Cyclophosphamide for ROHHAD Syndrome
NCT02441491Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Mar 2015
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cyclophosphamide in Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD), sponsored by Johns Hopkins University. Primary endpoints: Symptomatic improvement on the ROHHAD Symptoms Scale at 18 months and Safety and toxicity measured by CTCAE v4.0 at 18 months. Planned start Mar 2015; status: withdrawn.
02
Drugs
cyclophosphamide
03
Conditions
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD)
Beyond the preview
Go deeper on NCT02441491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441491.